Back to School: How biopharma can reboot drug development. Access exclusive analysis here
This month, ITMN and ROG will begin the multiple-ascending dose Phase Ib MAD trial
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury